Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > First Patient Dosed in Phase 1 Trial of TH1902

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on Mar 24, 2021 12:55pm

110 Views

Post# 32867074

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:First Patient Dosed in Phase 1 Trial of TH1902

Per protocol they will have to wait 21 days before injecting a higher dose, but since they will analyze the concentration of TH1902 and free docetaxel in the bloodstream over time, they will know well before 21 days what is going on. The data on bloodstream levels of docetaxel (PK/PD) leading to toxicity is well known. So it will be easy for them to know where they are in that respect.